查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014347

慢性特發性便秘治療市場：按治療方法、藥物類別、劑型、給藥途徑、處方狀態、最終用戶、分銷管道和年齡層分類 - 全球市場預測（2026-2032 年）

Chronic Idiopathic Constipation Therapeutic Market by Treatment Modality, Drug Class, Formulation Type, Route Of Administration, Prescription Status, End User, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性特發性便秘治療市場價值將達到 13.7 億美元，到 2026 年將成長到 14.8 億美元，到 2032 年將達到 23.5 億美元，複合年成長率為 7.93%。

主要市場統計數據
基準年（2025 年） 13.7億美元
預計年份（2026年） 14.8億美元
預測年份（2032年） 23.5億美元
複合年成長率 (%) 7.93%

以患者為中心，介紹慢性特發性便秘治療市場，並專注於未滿足的需求、治療的複雜性和不斷變化的臨床重點。

慢性特發性便秘是一種持續存在的臨床挑戰，它影響患者的生活品質，為臨床管理帶來許多複雜性，並整體治療方法的不斷創新。本文透過闡明以患者為中心的促進因素、臨床整體情況的需求以及藥物治療、醫療設備組合和行為療法的交叉融合，全面概述了該疾病的治療現狀。本文為後續的高階主管級總結奠定了基礎，旨在幫助商業領袖、臨床策略師和政策相關人員了解影響治療方法開發和推廣的各種因素。

透過分子層面的創新、數位化照護模式和以病人為中心的療效框架，帶來變革性的變化，重新定義慢性特發性便秘的治療。

慢性特發性便秘的治療格局正在經歷一場變革，這主要得益於科學、商業性和醫療服務領域的創新。分子標靶療法改變了人們對特定機制療效的預期，而對胃腸動力路徑日益成長的興趣也為臨床差異化治療開闢了新的途徑。同時，病患體驗和生活品質（QOL）作為評估指標的重要性日益凸顯，這重新定義了臨床試驗的成功標準，並影響支付者和處方醫師的認知。

對美國關稅調整如何重塑整個治療價值鏈的採購、製造地策略和下游分銷經濟進行全面評估。

美國新關稅政策的訂定，為參與治療性原料和成品供應鏈、定價以及跨境採購的相關人員帶來了更多策略變數。關稅變化正在影響上游生產決策，尤其是那些依賴海外供應商提供活性成分、特殊添加劑或契約製造合作夥伴的公司。因此，各公司正在重新評估籌資策略，以降低成本波動風險，同時確保供應的連續性和品質標準。

可操作的細分洞察，清楚顯示了對治療領域、給藥途徑、監管定位、治療方法和商業化分銷管道的影響。

了解藥物分類的細微差別對於制定針對慢性特發性便秘的差異化臨床和商業策略至關重要。藥物治療方法包括標靶5-HT4受體促效劑、氯離子通道活化劑、鳥苷酸環化酶C促效劑、滲透性瀉藥、刺激性瀉藥和軟便劑，每種藥物的動態特徵和耐受性均有所不同，這些因素會影響處方醫師的選擇和患者的依從性。給藥途徑方面，可分為口服和直腸給藥兩種形式。通常，口服製劑較適用於門診慢性疾病的治療，而直腸給藥製劑則用於針對性地緩解急性症狀或用於特定的臨床情況。

區域洞察：美洲、歐洲、中東和非洲以及亞太地區的醫療保健模式、支付方框架和監管預期方面的差異如何影響治療方法。

區域趨勢對慢性特發性便秘治療領域的臨床實務、支付方行為和監管預期均有顯著影響。在美洲，護理模式融合了基層醫療保健管理和胃腸病專家的參與，而獲取途徑則兼顧社區藥房的便利性和醫生主導管道。該地區病患支援服務和數位化用藥依從性工具也呈現快速成長，進而影響著產品價值提案和真實世界資料（REW）產生策略。

這項競爭格局分析重點闡述了創新、策略聯盟和供應鏈韌性如何塑造領導企業的差異化優勢和商業性優勢。

慢性特發性便秘治療市場的競爭動態呈現出兩極化的特點：既有成熟的製藥公司，也有專注於受體生物學、分泌作用機制和症狀治療的專業創新企業。主要企業優先考慮生命週期管理策略，包括拓展適應症、改進製劑以及提供證據證明其產品在耐受性和患者報告結局（PRO）方面具有優勢。同時，規模較小的生技公司和專業研發企業則傾向於開發小眾適應症、獨特的給藥技術或新穎的作用機制，以創造差異化和合作機會。

為商業、臨床和營運領導者提供切實可行的優先策略建議，以加速慢性特發性便秘治療的推廣，並降低取得和供應風險。

產業領導者應採取多管齊下的策略，將科學差異化與切實可行的商業化和市場准入策略結合。首先，他們應優先考慮在臨床開發早期階段就整合患者報告結局（PRO）和真實世界療效指標的研發項目，從而強化對處方醫生和支付方至關重要的證據體系。其次，他們應探索混合交付和支持模式，將藥物治療與數位化用藥依從性工具和標靶非藥物療法相結合，以改善患者療效並提高治療依從性。

透明嚴謹的檢驗調查方法，結合與專家的直接訪談、系統性的證據整合和三角驗證，確保了可靠且可操作的治療見解。

本執行摘要的調查方法結合了定性專家見解和系統性的證據整合，以確保研究結果的可靠性和可操作性。主要研究包括對臨床專家、胃腸病學家、支付方代表和商業領域領導者的深入訪談，從而提供有關臨床實踐趨勢、報銷趨勢和推廣障礙的背景資訊。這些訪談有助於為解讀臨床終點和區分治療方案提供可操作的見解。

結論強調，整合的臨床差異化、可操作的商業化策略和營運韌性對於確保治療價值和可近性至關重要。

總之，慢性特發性便秘的治療正處於一個轉折點，分子生物學的進步、醫療服務模式的創新以及政策趨勢在此交匯，既帶來了新的機遇，也帶來了營運上的複雜性。有效的治療策略應將強大的臨床差異化、以患者為中心的療效評估、靈活的准入機制以及穩健的供應鏈設計相結合。這些要素共同決定了治療藥物在不同醫療環境中的實際價值和永續性。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：慢性特發性便秘治療市場：依治療方法

  • 非藥物療法/輔助性治療
  • 藥物治療

第9章：慢性特發性便秘治療市場：依藥物類別分類

  • 鳥苷酸環化酶C (GC-C)促效劑
  • 滲透性瀉藥
  • 刺激性瀉藥
  • 血清素 5-HT4 受體促效劑
  • 容積擴張器
  • 軟便劑

第10章：慢性特發性便秘治療藥物市場：依劑型分類

  • 固態口服製劑
    • 藥片
    • 膠囊
  • 口服液體
    • 解決方案
    • 懸浮液
  • 直腸準備
    • 栓劑
    • 灌腸

第11章：慢性特發性便秘治療市場：依給藥途徑分類

  • 直腸
  • 口服

第12章：慢性特發性便秘治療市場：依處方狀態分類

  • 非處方藥
  • 處方藥

第13章：慢性特發性便秘治療市場：以最終用戶分類

  • 醫院
  • 專科胃腸病診所
  • 基層醫療診所
  • 居家醫療設施
  • 長期照護機構
  • 復健中心

第14章：慢性特發性便秘治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：慢性特發性便秘治療市場：依年齡層分類

  • 兒童患者
  • 成年患者

第16章：慢性特發性便秘治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 慢性特發性便秘治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：慢性特發性便秘治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國慢性特發性便秘治療市場

第20章：中國慢性特發性便秘治療市場

第21章 競爭情勢

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • AbbVie Inc.
  • Albireo Pharma, Inc. by Ipsen SA
  • ANI Pharmaceuticals, Inc.
  • Ardelyx Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • MSN Laboratories Private Limited
  • Norgine BV
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila Limited
Product Code: MRR-4311CE1A3392

The Chronic Idiopathic Constipation Therapeutic Market was valued at USD 1.37 billion in 2025 and is projected to grow to USD 1.48 billion in 2026, with a CAGR of 7.93%, reaching USD 2.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.37 billion
Estimated Year [2026] USD 1.48 billion
Forecast Year [2032] USD 2.35 billion
CAGR (%) 7.93%

A patient-centric introduction that frames chronic idiopathic constipation therapeutics by highlighting unmet needs, treatment complexity, and evolving clinical priorities

Chronic idiopathic constipation is a persistent clinical challenge that affects quality of life, imposes clinical management complexity, and stimulates sustained innovation across therapeutic modalities. This introduction frames the therapeutic landscape by clarifying patient-centric drivers, clinical unmet needs, and the intersection of pharmacology, device adjuncts, and behavioral therapies. It sets the stage for an executive-level synthesis designed to inform commercial leaders, clinical strategists, and policy stakeholders about the forces shaping therapeutic development and adoption.

Patients living with chronic idiopathic constipation often experience multifactorial symptom burdens that include infrequent bowel movements, stool hardness, and evacuation difficulties. Clinically, the condition demands treatments that balance efficacy with tolerability, adherence, and safety in often comorbid populations. In response, the research landscape has diversified to include novel receptor-targeted agents, intestinal secretagogues, osmotic and stimulant approaches, and adjunctive non-pharmacological interventions. These evolving therapeutic choices create both opportunities and complexity for clinical decision-making and commercialization.

Moreover, reimbursement dynamics, regulatory pathways, and patient access considerations increasingly influence clinical adoption and trial design. Consequently, stakeholders must evaluate therapeutic differentiation not only by mechanism of action but also by real-world outcomes, route of administration, and patient-reported benefits. This summary introduces the core themes addressed in the full analysis, emphasizing integrative approaches that align scientific innovation with pragmatic considerations for adoption, adherence, and long-term patient management.

Transformative shifts redefining chronic idiopathic constipation therapeutics through molecular innovation, digital care models, and patient-centered outcome frameworks

The therapeutic landscape for chronic idiopathic constipation is undergoing transformative shifts driven by scientific, commercial, and care-delivery innovations. Molecularly targeted agents have altered expectations around mechanism-specific benefits, while growing attention to gastrointestinal motility pathways has opened new avenues for clinical differentiation. At the same time, patient experience and quality-of-life endpoints are rising in prominence, reshaping how success is defined in clinical trials and influencing payer and prescriber perceptions.

Concurrently, digital health solutions and remote monitoring are beginning to augment traditional treatment paradigms, enabling more agile adherence support and symptom tracking that can inform personalized therapeutic adjustments. These technology-enabled approaches are catalyzing more patient-centered care models and offering manufacturers novel channels for demonstrating real-world value. Additionally, there is a visible shift towards combination strategies where pharmacological agents are paired with behavioral or device-based interventions to address complex symptom clusters.

Finally, regulatory and clinical trial frameworks are adapting to prioritize both objective and subjective endpoints that matter to patients. This evolution promotes development programs that integrate patient-reported outcomes and health economics considerations from early phases, thereby improving the alignment between clinical efficacy, payer acceptance, and long-term utilization. Overall, the convergence of scientific innovation, digital enablement, and patient-focused evidence generation is reshaping the competitive dynamics and strategic imperatives across the therapeutic ecosystem.

Comprehensive assessment of how U.S. tariff adjustments are reshaping procurement, manufacturing location strategies, and downstream distribution economics across the therapeutic value chain

The introduction of new tariff policies in the United States has introduced an additional strategic variable for stakeholders involved in the supply chain, pricing, and cross-border sourcing of therapeutic components and finished products. Tariff changes influence upstream manufacturing decisions, particularly for companies that rely on active pharmaceutical ingredient sourcing, specialized excipients, or contract manufacturing partners located overseas. Consequently, procurement strategies are being reevaluated to mitigate cost volatility while preserving supply continuity and quality standards.

Moreover, the tariff environment affects distribution economics by altering landed costs and potentially shifting preferred distribution channels. Manufacturers and distributors are increasingly exploring alternative routing, nearshoring, or domestic manufacturing investments to reduce exposure to import-related duties. These operational adjustments have downstream implications for pricing negotiations with payers and for the structuring of commercial contracts, particularly in segments where margin compression can impact investment in support programs or patient access services.

In parallel, tariff-driven cost pressures can accelerate consolidation among suppliers and third-party manufacturers as firms seek scale efficiencies to absorb added expense. For clinical development and commercialization, these dynamics can influence product launch timing and regional prioritization as companies weigh the trade-offs between global reach and localized cost structures. Stakeholders must therefore incorporate tariff scenario planning into procurement, pricing, and supply chain resilience strategies to sustain long-term access and competitive positioning.

Actionable segmentation insights articulating therapeutic class, administration route, regulatory positioning, treatment modality, and distribution channel implications for commercialization

Understanding segmentation nuances is essential to devising differentiated clinical and commercial strategies across chronic idiopathic constipation therapeutics. Drug class segmentation highlights that therapies span targeted 5-HT4 receptor agonists, chloride channel activators, guanylate cyclase-C agonists, osmotic laxatives, stimulant laxatives, and stool softeners, each offering distinct pharmacodynamic profiles and tolerability considerations that inform prescriber choice and patient adherence. Route of administration segmentation delineates between oral and rectal modalities, with oral options generally favored for chronic outpatient management and rectal preparations retained for targeted, acute relief or specific clinical scenarios.

Prescription status segmentation clarifies the strategic divide between over-the-counter and prescription drugs, where OTC availability can drive broad patient adoption and brand recognition but may limit clinical oversight, whereas prescription products support tighter diagnostic alignment and reimbursement pathways. Treatment modality segmentation separates non-pharmacological or adjunctive approaches from pharmacological interventions, underscoring the growing role of behavioral therapy, dietary counseling, pelvic floor rehabilitation, and device-assisted options as complements to drug therapy in comprehensive care pathways. Distribution channel segmentation observes that hospital pharmacies, online pharmacies, and retail pharmacies create distinct access and convenience profiles; hospital pharmacies are critical for inpatient care and specialist prescribing, retail pharmacies deliver community-based access and immediate fulfillment, and online pharmacies increasingly enable discreet ordering, home delivery, and subscription models that can enhance chronic therapy adherence.

These segmentation dimensions interact dynamically. For instance, a novel 5-HT4 receptor agonist delivered orally and positioned as a prescription therapy will require different market access, patient support, and distribution strategies compared with an osmotic laxative available OTC through retail and online pharmacy channels. Therefore, a cohesive strategy must harmonize clinical differentiation with route-of-administration preferences, regulatory positioning, adjunctive care pathways, and distribution capabilities to optimize both clinical outcomes and sustainable adoption.

Regional insights revealing how divergence in care models, payer frameworks, and regulatory expectations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption and access

Regional dynamics significantly influence clinical practice, payer behaviors, and regulatory expectations across the chronic idiopathic constipation therapeutic landscape. In the Americas, care models blend primary care management with specialist gastroenterology input, and access pathways emphasize both community pharmacy availability and physician-directed prescription channels. This region also sees rapid adoption of patient-support services and digital adherence tools, which shape product value propositions and real-world evidence generation strategies.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse reimbursement frameworks necessitate tailored country-level approaches. In many countries within this region, formulary placement and national therapeutic guidelines play outsized roles in shaping clinical adoption, and access is often mediated by health technology assessment processes that prioritize comparative effectiveness and cost-effectiveness evidence. Stakeholders must therefore adapt clinical evidence generation and pricing strategies to local HTA expectations and regional clinical practice patterns.

Asia-Pacific presents a varied landscape where demographic trends, healthcare infrastructure investments, and evolving reimbursement mechanisms drive differentiated adoption pathways. Urban centers often exhibit rapid uptake of novel therapeutics and digital health integrations, while rural and resource-constrained settings may rely more heavily on OTC options and community pharmacy networks. Across all regions, strategic partnerships with local distributors and payers can accelerate access while ensuring that patient education and adherence programs are culturally and logistically appropriate.

Competitive landscape analysis highlighting how innovation, strategic partnerships, and supply chain resilience are shaping leader differentiation and commercial advantage

Competitive dynamics in chronic idiopathic constipation therapeutics are characterized by a mix of established pharmaceutical companies and specialized innovators focused on receptor biology, secretagogue mechanisms, and symptomatic relief agents. Leading commercial players prioritize lifecycle management strategies including label expansions, formulation improvements, and evidence generation that demonstrates comparative tolerability and patient-reported outcome advantages. Meanwhile, smaller biotech firms and specialty developers often pursue niche indications, unique delivery technologies, or novel mechanisms to create differentiation and partnership opportunities.

Strategic collaborations between developers, contract manufacturers, and digital health vendors are increasingly common, creating integrated offerings that combine pharmacological therapies with adherence support and remote monitoring. This cross-sector teaming accelerates time-to-evidence for real-world effectiveness and enables more compelling payer conversations. Additionally, companies are investing in patient support infrastructure-such as education programs and nurse-led adherence services-to reduce discontinuation and improve therapeutic persistence, both of which are essential for chronic indications.

Finally, supply chain resilience and production quality are competitive differentiators. Firms that proactively address sourcing diversification, regulatory compliance in production facilities, and traceable distribution channels mitigate risk and can leverage reliability as a value proposition with large institutional purchasers and integrated delivery networks. Overall, incumbents that blend scientific rigor, operational excellence, and patient-centered support are positioned to lead in both clinical relevance and commercial viability.

Practical and prioritized strategic recommendations for commercial, clinical, and operational leaders to accelerate adoption and mitigate access and supply risks in chronic idiopathic constipation therapeutics

Industry leaders should adopt a multi-pronged strategy that aligns scientific differentiation with pragmatic commercialization and access tactics. First, prioritize development programs that integrate patient-reported outcomes and real-world effectiveness measures early in clinical development to strengthen evidence packages that matter to prescribers and payers. Second, consider hybrid delivery and support models that pair pharmacotherapy with digital adherence tools and targeted non-pharmacological interventions to enhance patient outcomes and foster treatment retention.

Next, strengthen supply chain resilience through diversified sourcing and consideration of localized manufacturing to mitigate tariff and geopolitical exposures. Concurrently, build flexible pricing and contracting approaches that can adapt to varied reimbursement environments and demonstrate value through outcomes-based agreements where appropriate. Also, invest in targeted market access capabilities to navigate regional regulatory and health technology assessment requirements efficiently, ensuring that dossiers emphasize comparative effectiveness and budget impact considerations relevant to local stakeholders.

Finally, cultivate strategic alliances with specialty pharmacies, patient advocacy groups, and clinical centers of excellence to accelerate uptake and support holistic care pathways. By combining robust clinical evidence with adaptive commercial models, operational reliability, and stakeholder engagement, industry leaders can maximize clinical impact while safeguarding long-term access and competitiveness.

Transparent and rigorous research methodology combining primary expert interviews, systematic evidence synthesis, and triangulation to ensure credible and actionable therapeutic insights

The research methodology underpinning this executive summary combines qualitative expert insight with systematic evidence synthesis to ensure robust, actionable findings. Primary research included in-depth interviews with clinical experts, gastroenterologists, payer representatives, and commercial leaders who provided contextual nuance on clinical practice trends, reimbursement dynamics, and adoption barriers. These interviews informed the interpretation of clinical endpoints and the practical implications for therapeutic differentiation.

Secondary research encompassed a methodical review of peer-reviewed clinical literature, regulatory guidance documents, treatment guidelines, and publicly available clinical trial registries to triangulate efficacy, safety, and outcome measure trends. Additionally, commercial and operational intelligence was sourced from industry disclosures, product labels, and distributor channel information to construct realistic supply chain and access scenarios. Throughout the analysis, data triangulation techniques were used to cross-validate findings from heterogeneous sources and to surface consistent themes relevant to stakeholders.

Analytical frameworks included segmentation matrices, scenario planning for policy impacts such as tariff shifts, and qualitative SWOT-style assessments tailored to therapeutic mechanisms and delivery channels. The methodology prioritized transparency in assumptions, a clear chain of evidence linking clinical findings to commercial implications, and iterative validation with subject-matter experts to ensure that conclusions are credible and operationally relevant.

Concluding synthesis emphasizing the necessity of integrated clinical differentiation, pragmatic commercialization strategies, and operational resilience to secure therapeutic value and access

In conclusion, chronic idiopathic constipation therapeutics are at an inflection point where molecular advances, care-delivery innovation, and policy dynamics converge to create new opportunities and operational complexities. Effective strategies will integrate robust clinical differentiation with patient-centered outcome measurement, adaptive access approaches, and resilient supply chain design. These elements collectively determine the real-world value and sustainability of therapeutic offerings in diverse healthcare environments.

Stakeholders who align clinical development with pragmatic commercialization-by embedding real-world evidence, leveraging digital supports, and tailoring regional access plans-will be better positioned to meet clinician and patient expectations while navigating reimbursement and distribution challenges. Furthermore, proactive contingency planning for policy and tariff developments, coupled with strategic partnerships across the value chain, will mitigate risk and preserve investment flexibility. Ultimately, the most successful programs will be those that translate scientific innovation into demonstrable patient benefit and accessible care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Idiopathic Constipation Therapeutic Market, by Treatment Modality

  • 8.1. Non-Pharmacological / Adjunct
  • 8.2. Pharmacological

9. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class

  • 9.1. Guanylate Cyclase-C (GC-C) Agonists
  • 9.2. Osmotic Laxatives
  • 9.3. Stimulant Laxatives
  • 9.4. Serotonin 5-HT4 Receptor Agonists
  • 9.5. Bulking Agents
  • 9.6. Stool Softeners

10. Chronic Idiopathic Constipation Therapeutic Market, by Formulation Type

  • 10.1. Solid Oral Formulations
    • 10.1.1. Tablets
    • 10.1.2. Capsules
  • 10.2. Liquid Oral Formulations
    • 10.2.1. Solutions
    • 10.2.2. Suspensions
  • 10.3. Rectal Formulations
    • 10.3.1. Suppositories
    • 10.3.2. Enemas

11. Chronic Idiopathic Constipation Therapeutic Market, by Route Of Administration

  • 11.1. Rectal
  • 11.2. Oral

12. Chronic Idiopathic Constipation Therapeutic Market, by Prescription Status

  • 12.1. Over-the-Counter (OTC) Medicines
  • 12.2. Prescription Medicines

13. Chronic Idiopathic Constipation Therapeutic Market, by End User

  • 13.1. Hospitals
  • 13.2. Specialty Gastroenterology Clinics
  • 13.3. Primary Care Clinics
  • 13.4. Home Care Settings
  • 13.5. Long Term Care Facilities
  • 13.6. Rehabilitation Centers

14. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel

  • 14.1. Hospital Pharmacies
  • 14.2. Online Pharmacies
  • 14.3. Retail Pharmacies

15. Chronic Idiopathic Constipation Therapeutic Market, by Age Group

  • 15.1. Pediatric Patients
  • 15.2. Adult Patients

16. Chronic Idiopathic Constipation Therapeutic Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Chronic Idiopathic Constipation Therapeutic Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Chronic Idiopathic Constipation Therapeutic Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Chronic Idiopathic Constipation Therapeutic Market

20. China Chronic Idiopathic Constipation Therapeutic Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc.
  • 21.6. Albireo Pharma, Inc. by Ipsen S.A.
  • 21.7. ANI Pharmaceuticals, Inc.
  • 21.8. Ardelyx Inc.
  • 21.9. Bausch Health Companies Inc.
  • 21.10. Bayer AG
  • 21.11. Dr. Reddy's Laboratories Ltd.
  • 21.12. Eisai Co., Ltd.
  • 21.13. Ferring B.V.
  • 21.14. Ironwood Pharmaceuticals, Inc.
  • 21.15. Lupin Limited
  • 21.16. Mallinckrodt plc
  • 21.17. MSN Laboratories Private Limited
  • 21.18. Norgine B.V.
  • 21.19. Sanofi S.A.
  • 21.20. Shionogi & Co., Ltd.
  • 21.21. Takeda Pharmaceutical Company Limited
  • 21.22. Zydus Cadila Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY NON-PHARMACOLOGICAL / ADJUNCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY NON-PHARMACOLOGICAL / ADJUNCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY NON-PHARMACOLOGICAL / ADJUNCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GUANYLATE CYCLASE-C (GC-C) AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GUANYLATE CYCLASE-C (GC-C) AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GUANYLATE CYCLASE-C (GC-C) AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SEROTONIN 5-HT4 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SEROTONIN 5-HT4 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SEROTONIN 5-HT4 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULKING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULKING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULKING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SPECIALTY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SPECIALTY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SPECIALTY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPE